SCHIZOPHRENIA. For Primary Care Providers. Project ECHO LA Adult Psychiatry ECHO June 25, 2014

Size: px
Start display at page:

Download "SCHIZOPHRENIA. For Primary Care Providers. Project ECHO LA Adult Psychiatry ECHO June 25, 2014"

Transcription

1 SCHIZOPHRENIA For Primary Care Providers Project ECHO LA Adult Psychiatry ECHO June 25, 2014 Curley L. Bonds, MD Medical Director Didi Hirsch Mental Health Services

2 SCHIZOPHRENIA The most common psychotic illness 7/1000 people develop the disorder in their lifetime Serious Mental Illness (SMI) 50%-90% of people with SMI have 1 or more chronic medical illness 1 Primary Care Experts are not expected to diagnose schizophrenia, but they should have a working knowledge of the illness, treatment and challenges 1 Gold, Kilbourne, Valenstein

3 CLINICAL SIGNIFICANCE Patients with schizophrenia die earlier than the general population, mostly from preventable treatable medical illnesses.

4 CLINICAL SIGNIFICANCE Patients with schizophrenia die earlier than the general population, mostly from preventable treatable medical illnesses. Higher rates of cardiovascular, infectious, respiratory, endocrine, and gastrointestinal disease are seen in patients with schizophrenia

5 CLINICAL SIGNIFICANCE Patients with schizophrenia die earlier than the general population, mostly from preventable treatable medical illnesses. Higher rates of cardiovascular, infectious, respiratory, endocrine, and gastrointestinal disease are seen in patients with schizophrenia Certain antipsychotic medications contribute to metabolic abnormalities more than others.

6 CLINICAL SIGNIFICANCE Patients with schizophrenia die earlier than the general population, mostly from preventable treatable medical illnesses. Higher rates of cardiovascular, infectious, respiratory, endocrine, and gastrointestinal disease are seen in patients with schizophrenia Certain antipsychotic medications contribute to metabolic abnormalities more than others. Routine physical health monitoring and targeted interventions, especially for cardiovascular disease and its risk factors, are key considerations when caring for this patient population.

7 DIFFERENTIAL DIAGNOSIS Psychosis Primary (psychiatric) Secondary ( organic ) Secondary Intoxication Withdrawal Medical Illness Infections Endocrinopathies Electrolyte and metabolic abnormalities Neurological processes (seizures, tumors, etc)

8 MEDICAL ASSESSMENT To Rule Out Organic Causes of Psychosis: Medical and family hx PE (with focused neuro exam) CBC Electrolytes, Ca++ BUN/Cr LFTs Vit B12 TSH HIV Florescent treponemal Antibody absorption test UA + Tox MRI Other: EEG, Cerulosplasmin, CXR, LP

9 6 Symptom Clusters of Schizophrenia Viron et al Schizophrenia for Primary Care

10 TREATMENT Should involve a multidisciplinary mental health treatment team to provide effective and comprehensive psychiatric care Medication Management Antipsychotics Dopamine blocking agents First Generation Typical older drugs (low to high potency) Side effects include orthostasis, sedation and anticholinergice side effects Second Generation Atypical newer drugs (5HT 2 and D 2 Antagonism) Have a lower liability for side effects Older: risperdone, olanzapine, queitapine, ziprasidone, and aripiprazole Newest: Paliperidone, asenapine, iloperidone, lurasidone Clozapine: requires routine WBC monitoring, + other side effects Therapy Case Management Psychosocial Rehabilitation

11 MEDICAL CARE Mortality rate for schizophrenia is 2-3x higher than in the general population. Elevated risk of death is due to higher rates of mortality from suicides and injuries, as well as multiple categories of medical illnesses. 5% will die by suicide Risk of suicide is 13x greater than the general population Patients often make contact with their PCP before the act Increase risk of CV Disease Higher rates of obesity, smoking, diabetes, HTN, dyslipidemia, and metabolic syndrome

12 ROUTINE MONITORING Personal and family history of obesity, diabetes, dyslipidemia, HTN, or DVD Smoking status Weight (BMI) Waist Circumference Blood Pressure Fasting Plasma Glucose Fasting lipid panel ECG Neurological Exam Prolactin Level Eye Examination (Chlorpromazine and quetiapine)

13 OBSTACLES & CHALLENGES Providing good care to patients with schizophrenia can be challenging. Symptoms of illness my disrupt engagement with a provider or clinic. Negative symptoms such as amotivation can present an obstacle to keeping appointments and following treatment plans. Paranoia may make it difficult for patient to feel comfortable. Therapeutic Nihilism Diagnostic overshadowing Stigma

14 REFERENCE Schizophrenia for Primary Care Providers: How to Contribute to the Care of a Vulnerable Patient Population Viron, Bagget, Hill, et al. The American Journal of Medicine (2012) 125,

Michael J. Bailey, M.D. OptumHealth Public Sector

Michael J. Bailey, M.D. OptumHealth Public Sector Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)

More information

EARLY ONSET SCHIZOPHRENIA

EARLY ONSET SCHIZOPHRENIA Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington

More information

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy

More information

Pharmacotherapy of psychosis and schizophrenia in youth

Pharmacotherapy of psychosis and schizophrenia in youth Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,

More information

Medication Audit Checklist- Antipsychotics - Atypical

Medication Audit Checklist- Antipsychotics - Atypical Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,

More information

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved

More information

ANTIPSYCHOTIC POLYPHARMACY

ANTIPSYCHOTIC POLYPHARMACY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction

More information

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second

More information

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names BLONANSERIN THERAPEUTICS Brands Lonasen see index for additional brand names Generic? No Class Atypical antipsychotic (serotonin dopamine antagonist; second-generation antipsychotic; also a potential mood

More information

Chapter 161 Antipsychotics

Chapter 161 Antipsychotics Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in

More information

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective

More information

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components

More information

Implementation of Performance Improvement Projects

Implementation of Performance Improvement Projects Implementation of Performance Improvement Projects Mary Marlatt-Dumas, Quality Manager, NMRE, Region 2 Diane L. Bennett, QI Coordinator/Compliance Officer, NorthCare Network, Region 1 Bill Phelps, Quality

More information

LURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names

LURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine

More information

Objectives. Pre Discussion Question #2. Disparity in Care Demographics

Objectives. Pre Discussion Question #2. Disparity in Care Demographics Objectives Implementation of a pharmacist driven metabolic monitoring protocol for second generation antipsychotics (SGAs) Jonathan Willett, PharmD PGY 1 Pharmacy Practice Resident Chickasaw Nation March

More information

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received

More information

February 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by

February 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,

More information

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

Severe Mental Illness and Diabetes. Charlie Place

Severe Mental Illness and Diabetes. Charlie Place Severe Mental Illness and Diabetes Charlie Place Intro Me Community Mental Health Nurse Case manager for Assertive Outreach Team in Leeds Severe Mental Illness (SMI) usually diagnosis of schizophrenia

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.

More information

The Brain and the Body: Medical Comorbidities in Psychiatric Illness. Kate Miley, CNP Psychiatric Nurse Practitioner, HCMC Adult Psychiatry Clinic

The Brain and the Body: Medical Comorbidities in Psychiatric Illness. Kate Miley, CNP Psychiatric Nurse Practitioner, HCMC Adult Psychiatry Clinic The Brain and the Body: Medical Comorbidities in Psychiatric Illness Kate Miley, CNP Psychiatric Nurse Practitioner, HCMC Adult Psychiatry Clinic The Problem: Health Disparities in SMI Life expectancy

More information

Schizophrenia: A Lifelong Illness

Schizophrenia: A Lifelong Illness Schizophrenia: A Lifelong Illness Medical Director Brain Health Exeter, NH Objectives Appreciate the historical perspectives of schizophrenia Describe our current understanding of the etiology of schizophrenia

More information

I received help from Bosch Health Care

I received help from Bosch Health Care John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early

More information

WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS

WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Treat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering

Treat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective

More information

#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by

#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by #CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Schizophrenia and Cognition Jeffrey A. Lieberman, MD Columbia University College of Physicians and Surgeons New York State Psychiatric

More information

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names ASENAPINE THERAPEUTICS Brands SAPHRIS see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin, norepinephrine receptor antagonist (DSN-RAn) Atypical

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file

More information

Practical Psychopharmacology for More Complex Mental Health Presentations

Practical Psychopharmacology for More Complex Mental Health Presentations MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 2: Antipsychotics & Mood Stabilizers Dr. Ajit Ninan & Joel Lamoure 1 : Who are we?

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics

More information

ESSENTIAL SHARED CAR E AGREEMENT FOR

ESSENTIAL SHARED CAR E AGREEMENT FOR E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some

More information

Antipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1

Antipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1 Antipsychotics Neuroleptics/ Major Tranquilizers Hiwa K. Saaed, PhD Pharmacology & Toxicology hiwa.saaed@univsul.edu.iq 2018-2019 12/5/18 1 Learning objectives Pharmacy students should: be familiar with

More information

Psychotropics and Foster Care: Challenge or Opportunity?

Psychotropics and Foster Care: Challenge or Opportunity? Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love, PharmD, BCPP, FASHP Professor and Director, Mental Health Program University of Maryland School of Pharmacy Objectives At the conclusion

More information

Treatment of Schizophrenia

Treatment of Schizophrenia Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Physical Health Management: Why it s important for adolescents and young adults in mental health services

Physical Health Management: Why it s important for adolescents and young adults in mental health services Physical Health Management: Why it s important for adolescents and young adults in mental health services Early Intervention Service Wellington Lauren Heath and Erin Dawson Introduction Second generation

More information

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics Antipsychotics: The Essentials Module 5: A Primer on Selected Antipsychotics Slide 1 Recently approved antipsychotics Iloperidone (Fanapt) - 2009 Asenapine (Saphris, Sycrest) - 2009 Lurasidone (Latuda)

More information

Comparison of Atypical Antipsychotics

Comparison of Atypical Antipsychotics PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of

More information

Schizophrenia. Introduction. Overview and Facts

Schizophrenia. Introduction. Overview and Facts Introduction is a chronic, severe and disabling brain disease that typically shows its first clear symptoms in late adolescence or early adulthood. It is one of several types of Psychotic Disorders. It

More information

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 Potential control of antipsychotic-induced hyperprolactinemia and

More information

Schizophrenia and Related Psychotic Disorders

Schizophrenia and Related Psychotic Disorders and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Psychopharmacological treatment of first episode psychosis

Psychopharmacological treatment of first episode psychosis Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center

More information

TRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names

TRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names TRIFLUOPERAZINE THERAPEUTICS Brands Stelazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

ILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No

ILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No ILOPERIDONE THERAPEUTICS Brands FANAPT see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Atypical antipsychotic

More information

PRIMARY CARE MANAGEMENT OF OBESITY

PRIMARY CARE MANAGEMENT OF OBESITY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences PRIMARY CARE MANAGEMENT OF OBESITY LYDIA CHWASTIAK MD, MPH ASSOCIATE PROFESSOR UNIVERSITY OF WASHINGTON DEPARTMENT

More information

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,

More information

Table of Contents. 1.0 Policy Statement...1

Table of Contents. 1.0 Policy Statement...1 Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT

More information

CHLORPROMAZINE. THERAPEUTICS Brands Thorazine see index for additional brand names

CHLORPROMAZINE. THERAPEUTICS Brands Thorazine see index for additional brand names CHLORPROMAZINE THERAPEUTICS Brands Thorazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Conventional antipsychotic

More information

Collaborating, Co-managing and Facilitating Metabolic Improvement in Patients with Severe Mental Illness (SMI)

Collaborating, Co-managing and Facilitating Metabolic Improvement in Patients with Severe Mental Illness (SMI) Collaborating, Co-managing and Facilitating Metabolic Improvement in Patients with Severe Mental Illness (SMI) 14 th Canadian Collaborative Mental Health Care Conference Montréal, Québec June 28, 2013

More information

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental

More information

Minimising the Impact of Medication on Physical Health in Schizophrenia

Minimising the Impact of Medication on Physical Health in Schizophrenia Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,

More information

SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009

SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2

More information

Aggression (Severe) in Children under Age 6

Aggression (Severe) in Children under Age 6 Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric

More information

Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug

Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Mohammad Naeem Niazy, MRCP, FRCPI* Ghassan Baidas, MRCP, FRCPI* Thomas

More information

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, antiemetic) Commonly Prescribed

More information

Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID

Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Although not considered first line treatment in children with ASD and ID, depending on the severity of symptoms, some medications

More information

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors

More information

Chapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses

Chapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

What Team Members Other Than Prescribers Need To Know About Antipsychotics

What Team Members Other Than Prescribers Need To Know About Antipsychotics What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications

Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine

More information

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric

More information

PALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names

PALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names PALIPERIDONE THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn)

More information

AMISULPRIDE. THERAPEUTICS Brands Solian see index for additional brand names. Generic? No

AMISULPRIDE. THERAPEUTICS Brands Solian see index for additional brand names. Generic? No AMISULPRIDE THERAPEUTICS Brands Solian see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Atypical antipsychotic (benzamide; possibly

More information

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine

More information

Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness

Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness Sally Ricketts, M.D. New York State Office of Mental Health Bureau of Evidence-Based Services

More information

Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications

Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications JOHN M. DAVIS, MD Professor of Psychiatry University of Illinois at Chicago Chicago, Illinois and STEFAN LEUCHT, MD Klinik

More information

LOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic?

LOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic? LOXAPINE THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor

More information

Rexulti (brexpiprazole)

Rexulti (brexpiprazole) Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia

More information

Schizophrenia and bipolar disorders are lifelong

Schizophrenia and bipolar disorders are lifelong THE STANDARD OF CARE IN TREATING PSYCHIATRIC DISORDERS Peter J. Weiden, MD,* and David G. Daniel, MD ABSTRACT In recent years, several guidelines and algorithms have appeared to help clinicians address

More information

The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in

The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.

More information

6/20/2014. Overview. Learning Objectives. Review of Schizophrenia. Diagnosis (DSM 5) Disclosure

6/20/2014. Overview. Learning Objectives. Review of Schizophrenia. Diagnosis (DSM 5) Disclosure Overview Diagnosis and proposed pathophysiology of schizophrenia Rating scales used in schizophrenia Madness and Confusion of Mind: Schizophrenia Pharmacotherapy Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual

More information

Madness and Confusion of Mind: Schizophrenia Pharmacotherapy. Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual Meeting 2014

Madness and Confusion of Mind: Schizophrenia Pharmacotherapy. Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual Meeting 2014 Madness and Confusion of Mind: Schizophrenia Pharmacotherapy Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual Meeting 2014 Learning Objectives 1. Apply the current evidence on the efficacy of pharmacologic and

More information

Date Revision Log Updated By 11/30/2015 Initial Draft E. Pape

Date Revision Log Updated By 11/30/2015 Initial Draft E. Pape Title: Integrated Behavioral Health and Primary Care Medication Management Guidelines Date Created: 11/30/2015 Date Modified: Date Approved by Board of Directors: 12/08/2015 Clinical Guideline # CGC-CG-23

More information

Antipsychotic Prior Authorization Request

Antipsychotic Prior Authorization Request Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

In recent years, reports of diabetes, diabetic

In recent years, reports of diabetes, diabetic A REVIEW OF METABOLIC ISSUES IN ATYPICAL ANTIPSYCHOTIC TREATMENT John W. Newcomer, MD, * and Henry A. Nasrallah, MD ABSTRACT Reports of diabetes, diabetic ketoacidosis, hyperglycemia, and dyslipidemias

More information

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP

More information

Reviews and Overviews. Physical Health Monitoring of Patients With Schizophrenia

Reviews and Overviews. Physical Health Monitoring of Patients With Schizophrenia Reviews and Overviews Physical Health Monitoring of Patients With Schizophrenia Stephen R. Marder, M.D. Susan M. Essock, Ph.D. Alexander L. Miller, M.D. Robert W. Buchanan, M.D. Daniel E. Casey, M.D. John

More information

MANAGING ANTIPSYCHOTIC INDUCED METABOLIC SYNDROME TO IMPROVE TREATMENT ADHERENCE AND QUALITY OF LIFE IN GALLATIN COUNTY. Shelby Leigh Frye.

MANAGING ANTIPSYCHOTIC INDUCED METABOLIC SYNDROME TO IMPROVE TREATMENT ADHERENCE AND QUALITY OF LIFE IN GALLATIN COUNTY. Shelby Leigh Frye. MANAGING ANTIPSYCHOTIC INDUCED METABOLIC SYNDROME TO IMPROVE TREATMENT ADHERENCE AND QUALITY OF LIFE IN GALLATIN COUNTY by Shelby Leigh Frye A professional project submitted in partial fulfillment of the

More information

Extrapyramidal Symptoms Associated with Antipsychotic Use

Extrapyramidal Symptoms Associated with Antipsychotic Use Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and

More information

Pharmacists in Medication Adherence in Psychiatric Patients

Pharmacists in Medication Adherence in Psychiatric Patients Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy

More information

Acute Treatment of Schizophrenia Multiple-treatments meta-analysis

Acute Treatment of Schizophrenia Multiple-treatments meta-analysis Acute Treatment of Schizophrenia Multiple-treatments meta-analysis Prof. Stefan Leucht Vice chairman Department of Psychiatry and Psychotherapy Technische Universität München Aims I. To understand the

More information

Kelly Godecke, MD Department of Psychiatry University of Utah

Kelly Godecke, MD Department of Psychiatry University of Utah Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar

More information

Why are NICE guidelines and standards important and relevant to us?

Why are NICE guidelines and standards important and relevant to us? Why are NICE guidelines and standards important and relevant to us? Dr Liz England GP, Laurie Pike health centre RCGP Mental Health Clinical and Commissioning Lead SWB CCG Mental Health Lead NIHR Clinical

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Antipsychotic Medication

Antipsychotic Medication Antipsychotic Medication Mary Knutson, RN 3-7-12 Mosby items and derived items 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 1 Clinical Uses of Antipsychotics Short-term: in severe depression and

More information

Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study. Finding Clarity in the Midst of Uncertainty

Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study. Finding Clarity in the Midst of Uncertainty Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study Finding Clarity in the Midst of Uncertainty Agenda Medication adherence in serious mental illness Consequences

More information

QUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes

QUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes QUETIAPINE THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin multimodal (DS-MM) Atypical antipsychotic

More information

First Episode Schizophrenia

First Episode Schizophrenia First Episode Schizophrenia Abigail Donovan, M.D. Assistant Professor of Psychiatry, Harvard Medical School Director, First Episode and Early Psychosis Program MGH Schizophrenia Program Massachusetts General

More information

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08. Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important

More information

Physical health of those with serious mental illness.

Physical health of those with serious mental illness. Physical health of those with serious mental illness. How Compass Health PHO is improving the service for our population Lynley Byrne Clinical Leader Compass Health PHO June 2016 Total Population Compass

More information